EGFR and non-small cell lung carcinoma: Patterns-of-failure studies in advanced NSCLC patients treated with chemotherapy or EGFR-TKI showed that most progression occurred only at sites of disease known to exist at baseline, rather than in new sites (10–13), and these studies advanced the development of EGFR therapeutic.